Prospective biomarker study shows CSF ctDNA clearance predicts outcomes in PCNSL, suggesting its potential.
This prospective biomarker study evaluated serial CSF ctDNA monitoring in newly diagnosed PCNSL treated with R-MO induction therapy. Mid-treatment ctDNA clearance was significantly associated with complete response and superior progression-free survival, showing stronger predictive value than interim PET-CT in this cohort. These findings support CSF ctDNA clearance as a promising molecular biomarker for early response assessment in PCNSL.
No takes yet. Share an insight, caveat, or question.
Sheng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: